Norbrook Laboratories, Ltd. announces the FDA approval of new Enroflox 100 (enrofloxacin) available for swine producers via a veterinary prescription. Norbrook, a global veterinary pharmaceutical company, says its new product for the treatment and control of Swine Respiratory Disease (SRD) has the same active ingredient, formulationand dose regimen as Baytril 100* (enrofloxacin).
New Enroflox100 is effective against four major SRD-causing bacteria, including Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis. Enrofloxacin has quickly become the choice of veterinarians and producers to treat and control SRD since its introduction in 2008.
“Veterinarians, integrators and pork producers have been asking for a cost-effective alternative to the popular Baytril100 for several years. We are excited to introduce this new generic version to this audience,” announces Chip Whitlow, Marketing Manager, Norbrook, Inc. “The big difference veterinarians, integrators and swine producers will notice is the lower per-dose cost in swine when compared to Baytril 100.”
Enroflox100 will be available from veterinarians in 100 mL and 250 mL bottles to fit any size operation. For more information about new Enroflox100, contact your veterinarian or local animal-health products supplier or Norbrook, Inc. at www.norbrookinc.com.
For use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals. Swine intended for human consumption must not be slaughtered within 5 days ofreceiving a single-injection dose. Use with caution in animals with known or suspected CNS disorders. Observe label directions and withdrawal times. See product labeling for full product information.
*Baytril is a registered trademark of Bayer